Frenkel Ran
SEC CIK 1623108 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | EVP, Chief Dev. Off | 168.3K | — | $72.2K | 4 | 2022-02-07 | 2022-02-28 |
Most active insiders at KPTI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Paulson Richard A. | Pres, CEO, Dir | — | $137.2K |
| 2 | Poulton Stuart | EVP, Chief Development Off | — | $56.4K |
| 3 | Rangwala Reshma | EVP, Chief Medical Off | — | $55.6K |
| 4 | Cheng Sohanya Roshan | EVP, Chief Commercial Off | — | $46.4K |
| 5 | Mano Michael | SVP, GC, Sec | — | $35.7K |
| 6 | Macomber Lori | EVP, CFO, Treas | — | $10.2K |
| 7 | Abate Kristin | CAO | — | $10.0K |
| 8 | Su Zhen | Dir | — | — |
| 9 | Oliger Christy J. | Dir | — | — |
| 10 | Schor Chen | Dir | — | — |
Frenkel Ran made no open-market trades at KPTI in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-02 | 2022-02-28 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | EVP, Chief Dev. Off | S - Sale | $10.24 | -1,663 | 168.3K | -1.0% | -$17.0K |
| D | 2022-03-02 | 2022-02-28 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | EVP, Chief Dev. Off | A - Grant | $0.00 | +68.2K | 170.0K | +67% | $0 |
| 2022-02-22 | 2022-02-17 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | EVP, Chief Dev. Off | S - Sale | $12.12 | -2,929 | 101.7K | -3% | -$35.5K | |
| 2022-02-09 | 2022-02-07 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | EVP, Chief Dev. Off | S - Sale | $9.86 | -1,991 | 104.6K | -2% | -$19.6K |
Purchase Sale Sale after option exercise All abbreviations